Digital Transformation in Pharmaceutical R&D in a Midsized Company: Unlocking Innovation Through Human and Organizational Factors

Abstract

Digital transformation presents a strategic imperative for the pharmaceutical industry, particularly within research and development (R&D), where it promises accelerated time to market and enhanced operational efficiency. Building on the foundation of the People Coordination, Ownable Focus Areas, Long-Term Roadmap, Common Digital Alphabet, Reporting, and Monitoring (P.O.L.A.R.) Star framework, this article delves into the critical soft elements —human and organizational factors—essential for deploying a successful digital transformation in the pharmaceutical R&D of a midsized company. While technological roadmaps provide structure and serve as a blueprint, sustainable results depend on an organization’s ability to evolve both in its culture and approach to change. In this context, implementing new capabilities—such as centralized R&D data governance and a common data model—not only requires a transparent approach to data, strong digital leadership, and deep expertise but also triggers an organizational rethinking to support this evolution. Based on the needs and current evolution phase of the digital transformation journey of the company, this rethinking can be represented by a “federated” approach based on cross-functional teams, a digital unit to centralize activities and solutions, or a hybrid model combining elements of both. In summary, this article offers a focused, actionable guide to managing digital transformation in pharmaceutical R&D. It explores the concept of a digital unit or a cross-functional team as strategic options, evaluated to guide intentional, structured operations within a digital reorganization; it also highlights the cultural shift needed for long-term sustainability.